Hepatotoxicity, a global problem with local features: Toward the creation of a Pan-American Hepatotoxicity Network;Hepatotoxicidad, un problema global con especificidades locales: hacia la creación de una Red Hispano Latinoamericana de Hepatotoxicidad

Gastroenterologia y Hepatologia

Volumn 34, Issue 5, 2011, Pages 361-368

  Lucena, María Isabel ^a   Cohen, Henry ^b   Hernández, Nelia ^b   Bessone, Fernando ^c   Dacoll, Cristina ^b   Stephens, Camilla ^a   Borraz, Yolanda ^a   Ulzurrun, Eugenia ^a   Bruguera, Miguel ^d   Andrade, Raúl J ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b HOSPITAL DE CLÍNICAS   (Uruguay)

^c UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Hepatotoxicity; Pan American Hepatotoxicity Network; Registry; Spanish Hepatotoxicity Registry; Toxic liver damage

Indexed keywords

ARTICLE; CLINICAL FEATURE; LIVER DISEASE; LIVER TOXICITY; POSTMARKETING SURVEILLANCE; TOXIC HEPATITIS;

DRUG-INDUCED LIVER INJURY; HUMANS; LATIN AMERICA; REGISTRIES; SPAIN;

EID: 79955957417     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/j.gastrohep.2011.01.003     Document Type: Article

References (37)

1. Ostapowicz G., Fontana R.J., Schiødt F.V., Larson A., Davern T.J., Han S.H., et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002, 137:947-954.
2. Wei G., Bergquist A., Broome U., Lindgren S., Wallerstedt S., Almer S., et al. Acute liver failure in Sweden: etiology and prognosis. J Internal Med. 2007, 262:393-401.
3. Mindikoglu A.L., Magder L.S., Regev A. Outcome of liver transplantation for drug-induced acute liver failure in the United States: analysis of the United Network for Organ Sharing Database. Liver Transpl. 2009, 15:719-729.
4. de Abajo F.J., Montero D., Madurga M., Garcia-Rodriguez L.A. Acute and clinically relevant drug-induced liever injury:a population based case-control study. Br J Clin Pharmacol. 2004, 58:71-80.
5. Sgro C., Clinard F., Ouazir K., Chanay H., Allard C., Guilleminet C., et al. Incidence of drug-induced hepatic injuries: a French-population based study. Hepatology. 2002, 36:451-455.
6. Andrade R.J., Lucena M.I., Fernández M.C., Pelaez G., Pachkoria K., García-Ruiz E., et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish Registry over a 10-year period. Gastroenterology. 2005, 129:512-521.
7. Fontana R.J. Approaches to the study of drug-induced liver injury. Clin Pharmacol Ther. 2010, 88:416-419.
8. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Reviews Drug Discov. 2005, 4:489-499.
9. García-Cortés M., Borraz Y., Lucena M.I., Peláez G., Salmeron J., Diago M., et al. Liver injury induced by " natural remedies": an analysis of cases submitted to the Spanish Liver Toxicity Registry. Rev Esp Enferm Dig. 2008, 100:688-695.
10. Suzuki A., Andrade R.J., Björnsson E., Lucena M.I., Lee W.M., Yuen N.A., et al. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase™: unified list based on international collaborative work. Drug Saf. 2010, 33:503-522.
11. Fontana R.J., Seeff L.B., Andrade R.J., Björnsson E., Day C.P., Serrano J., et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology. 2010, 52:730-742.
12. Devarbhavi H., Dierkhising R., Kremers W.K., Sandeep M.S., Karanth D., Adarsh C.K. Single-center experience with drug-induced liver injury from india: causes, outcome, prognosis, and predictors of mortality. Am J Gastroenterol. 2010, 105:2396-2404.
13. Bessone F., Colombato L., Fassio E., Reggiardo M.V., Vorobioff J., Tanno H. The spectrum of nimesulide-induced-hepatotoxicity. An overview. Anti-Inflamm & Anti-Allergy Agents Med Chem. 2010, 9:355-365.
14. Bakke O.M., Manocchia M., de Abajo F., Kaitin K.I., Lasagna L. Drug safety discontinuations in the United Kingdom, the United Status, and Spain from 1974 through 1993: a regulatory perspective. Clin Pharmacol Ther. 1995, 58:108-117.
15. Walgren J.L., Mitchell M.D., Thompson D.C. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit Rev Toxicol. 2005, 35:325-361.
16. Lucena M.I., Andrade R.J., Fernandez M.C., Pachkoria K., Pelaez G., Durán J.A., et al. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. Hepatology. 2006, 44:850-856.
17. Andrade R.J., Lucena M.I. Drug-induced hepatotoxicity. N Engl J Med. 2003, 349:1974-1976.
18. Lucena M.I., Camargo R., Andrade R.J., Perez-Sanchez C., Sanchez de la Cuesta F. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology. 2001, 33:123-130.
19. Rochon J., Protiva P., Seeff L.B., Fontana R.J., Liangpunsakul S., Watkins P.B., et al. Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology. 2008, 48:1175-1183.
20. Garcia-Cortes M., Stephens C., Lucena M.I., Fernandez-Castañer A., Andrade R.J. Causalitty assessment methods in drug-induced liver injury. Strength and weaknesses. J Hepatol 2010, 10.1016/j.jhep.2011.02.007.
21. Kaplowitz N. Drug-induced liver disorders:implications for drug development and regulation. Drug Saf. 2001, 24:483-490.
22. de Abajo F.J., Montero D., Madurga M., Palop R. Análisis y gestión de riesgos en farmacovigilancia. Organización de la Farmacovigilancia en España. El ensayo clínico en España 2001, 191-216. Farmaindustria, Serie Científica Madrid, Madrid. A.G. Garcia, L. Gandia (Eds.).
23. Agarwal V.K., McHutchison J.G., Hoofnagle J.H. Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol. 2010, 8:463-470. for the Drug-Induced Liver Injury Network (DILIN).
24. Andrade R.J., Lucena M.I., Garcia-Cortes M. Utilidad de los registros de hepatotoxicidad por fármacos. Gastroenterol Hepatol. 2001, 24:250-255.
25. Andrade R.J., Lucena M.I., Martín-Vivaldi R., Fernández M.C., Nogueras F., Pelaez G., et al. Acute liver injury associated with the use of ebrotidine, a new H2-receptor antagonist. J Hepatol. 1999, 31:641-646.
26. Lucena M.I., Cueto R., Stephens C., Cabello M.R., Robles M., Andrade R.J. Genética y hepatotoxicidad. Gastroenterol Hepatol. 2010, 33(Suppl 1):10-21.
27. Andrade R.J., Lucena M.I., Kaplowitz N., García-Muņoz B., Borraz Y., Pachkoria K., et al. Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology. 2006, 44:1581-1588.
28. Björnsson E., Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005, 42:481-489.
29. Chalasani N., Fontana R., Bonkovsky H., Watkins P., Davern T., Serrano J., et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterolology. 2008, 135:1924-1934.
30. Daly A.K., Donaldson P.T., Bhatnagar P., Shen Y., Pe'er I., Floratos A., et al. HLA-B 5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009, 41:816-819.
31. The international Severe Adverse Events Consortium's Phenotyping Standardization Project (PSP). Disponible en: http://www.saeconsortium.org.
32. Sánchez Albornoz N. La explosión demográfica. En: La población en America Latina: desde los tiempos precolombinos al año 2025. Madrid: Alianza Editorial; 1994. p. 211.
33. Leyva-Flores R., Erviti-Erice J., Kageyama-Escobar M.L., Arredondo A. Medical prescription, drug access and drug expenditure amonghealth service users in Mexico. Salud Publica Mex. 1998, 40:24-31.
34. Lucena M.I., Garcia-Martin E., Andrade R.J., Martinez C., Stephens C., Ruiz J.D., et al. Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury. Hepatology. 2010, 52:303-312.
35. Donaldson P.T., Daly A.K., Henderson J., Graham J., Pirmohamed M., Bernal W., et al. Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J Hepatol. 2010, 53:1049-1053.
36. Stephens C., Lopez-Nevot M.I., Lucena M.I., Ruiz-Cabello F., Ulzurrun E., Cabello M.C., et al. The HLA class I B 1801 allele influences hepatocellular expression of amoxicillin-clavulanate liver damage and outcome in Spanish patients. J Hepatol. 2010, 52(Suppl 1):S439.
37. Contreras J., Poniachik J., Planzer M., Lazarte R., Smok G., Oksenberg D., et al. Daño hepático por fármacos: características clínicas e histológicas en 33 casos. Rev Med Chile. 2003, 131:1128-1134.